N-METHYL-D-ASPARTATE (NMDA) RECEPTORS: POTENTIAL TARGET FOR NEURODEGENERATIVE DISEASES

Sandip Zine, Rakesh Somani, Pooja Dubey, Sarita Kunchikorve

Abstract


The N-methyl-D-aspartate (NMDA) receptor is a glutamate receptor which is the predominant molecular device for controlling synaptic plasticity and memory function. N-methyl-D-aspartate is the name of a selective agonist that binds to NMDA receptors but not to other 'glutamate' receptors. Neurodegenerative diseases are caused due to neurodegeneration. NMDA with Glutamate bound results in increase of intracellular Calcium levels which results in slow degeneration of neurons. Hence, for neuroprotection one can target NMDA receptor antagonists. The use of low affinity NMDA antagonists like Memantine for reducing NMDA receptor-mediated excitotoxicity features the importance of developing NMDA receptor-based therapies with different pharmacological profiles for treating brain disorders.. The success of this strategy could be further enhanced by better understanding the subunit-specific mechanisms involved in individual disorders. The main objective of this is development of new NMDA receptor-based treatments with greater therapeutic benefits and fewer side effects.

Keywords


Excitotoxicity, glutamate, Memantine, neurodegeneration, NMDA antagonists

Full Text:

Full text in pdf

References


Akazawa C., Shigemoto R., Bessho Y., Nakanishi S., Mizuno N. (1994). Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. Journal of Comparative Neurology, 347, p.150–160.

Allard, P., Alafuzoff I., Carlsson A., et al. (2008). Loss of Dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer’s disease. European Neurology , 30, p.181–185.

Auberson, YP., Acklin, P., Bischoff, S., et al.(1999). N-Phosphonoalkyl-5-aminomethylquinoxaline-2, 3-diones: In vivo active AMPA and NMDA(glycine) antagonists. Bioorganic & Medicinal Chemistry Letters, 9, p.249–254.

Bakshi, VP., Geyer, MA. (1998). Multiple Limbic Regions Mediate the Disruption of Prepulse Inhibition Produced in Rats by the Noncompetitive NMDA Antagonist Dizocilpine. Journal of Neuroscience. , 18, p.8394–8401.

Baron, BM., Harrison, BL., Miller FP., et al. (1990). Activity of 5,7-Dichiorokynurenic Acid, a Potent Antagonist at the N-Methyl-D-Aspartate Receptor-Associated Glycine Binding Site. Molecular Pharmacology, 38, p.554–561.

Baron, BM., Siegel, BW., Slone, AL., Harrison, BL., Palfreyman, MG., Hurt SD. (1991). [3H]5, 7-Dichlorokynurenic acid, a novel radioligand labels NMDA receptor-associated glycine binding sites. European Journal of Pharmacology: Molecular Pharmacology. ,206, p.149–154.

Bigge, CF., Johnson, G., Ortwine, DF., et al. (1992). Exploration of N-phosphonoalkyl-, N-phosphonoalkenyl-, and N-(phosphonoalkyl)phenyl-spaced .alpha.-amino acids as competitive N-methyl-D-aspartic acid antagonists. Journal of Medicinal Chemistry., 35, p. 1371–1384.

Blanpied, TA. (2005). Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. Journal of Neuroscience., 25, p. 3312–3322.

Boller, F., Mizutani, T., Roessmann, U., Gambetti, P. (1980). Parkinson disease, dementia, and alzheimer disease: Clinicopathological correlations. Annals of Neurology. 7, p. 329–335.

Bowen, WD. (2007). Sigma receptors: Recent advances and new clinical potentials. Pharmaceutica Acta Helvetiae. , 74, p. 211–218.

Brown, D., Krupp, J. (2006). N-Methyl-D-Aspartate receptor (NMDA) antagonists as potential pain Therapeutics.Current Topics in Medicinal Chemistry., 6, p. 749–770.

Burger A. (2003). Burger’s medicinal chemistry and drug discovery: V. 4: Autocoids, diagnostics and drugs from new biology, 6th ed., John Wiley & Sons, United States.

Carter, C. (1982). Topographical distribution of possible glutamatergic pathways from the frontal cortex to the striatum and substantia nigra in rats. Neuropharmacology, 21, p. 379–383.

Carter, CJ., L’Heureux, R., Scatton, B. (1988). Differential control by N-Methyl-D-Aspartate and Kainate of Striatal Dopamine release in vivo: A Trans-Striatal dialysis study. Journal of Neurochemistry., 51, p. 462–468.

Chéramy, A., Romo, R., Godeheu, G., Baruch, P., Glowinski, J. (1986). In vivo presynaptic control of dopamine release in the cat caudate nucleus—II. Facilitatory or inhibitory influence ofl-glutamate. Neuroscience., 19, p. 1081–1090.

Crowder, JM., Bradford, HF. (1987). Inhibitory effects of noradrenaline and dopamine on calcium influx and neurotransmitter glutamate release in mammalian brain slices. European Journal of Pharmacology , 143, p. 343–352.

Cull-Candy, S., Brickley, S., Farrant, M. (2001). NMDA receptor subunits: Diversity, development and disease.Current Opinion in Neurobiology., 11, p. 327–335.

Cummings, JL. (1986). Subcortical dementia. Neuropsychology, neuropsychiatry, and pathophysiology. British Journal of Psychiatry, 149, p. 682–697.

Di Fabio, R., Conti, N., De Magistris, E., et al. (1999). Substituted analogues of GV150526 as potent Glycine binding site antagonists in animal models of cerebral Ischemia. Journal of Medicinal Chemistry., 42, p. 3486–3493.

Earley, WG., Kumar, V., Mallamo, JP., et al. (1995). Novel Benzo[b]quinolizinium Cations as uncompetitive N-Methyl-D-aspartic acid (NMDA) antagonists: The relationship between log D and Agonist independent (closed) NMDA channel block. Journal of Medicinal Chemistry., 38, p. 3586–3592.

Fonnum, F. (1984). Glutamate: A neurotransmitter in mammalian brain. Journal of Neurochemistry, 42, p. 1–11.

Francis, PT., Sims, NR., Procter, AW., Bowen, DM. (1993). Cortical pyramidal Neurone loss May Cause Glutamatergic Hypoactivity and cognitive impairment in Alzheimer’s disease: Investigative and therapeutic perspectives.Journal of Neurochemistry, 60, p. 1589–1604.

Galli, T., Desce, JM., Artaud, F., Kemel, M., Chéramy, A., Glowinski, J. (1992). Modulation of GABA release by α-amino-3-hydroxy-5-methylisoxazole-4-propionate and N-methyl-d-aspartate receptors in matrix-enriched areas of the rat striatum. Neuroscience., 50, p. 769–780.

Hansen, L., Salmon, D., Galasko, D., et al. (1990). The Lewy body variant of Alzheimer’s disease: A clinical and pathologic entity. Neurology., 40, p. 1–1.

Hollmann, M. (1994). Cloned glutamate receptors. Annual Review of Neuroscience., 17, p. 31–108.

Hu, L-Y., Guo, J., Magar, SS., Fischer, JB., Burke-Howie, KJ., Durant, GJ. (1997). Synthesis and pharmacological evaluation of N -(2, 5-Disubstituted phenyl)- N “-(3-substituted phenyl)- N ”-methylguanidines as N -methyl- d -aspartate receptor ion-channel Blockers. Journal of Medicinal Chemistry., 40, p. 4281–4289. .

Identification of novel drug leads for NMDA receptor implicated in schizophrenia from Indian traditional herbs. Paper presented at: International conference on Intelligent Systems, Data Mining and Information Technology (ICIDIT) 2014http://iieng.org/images/proceedings_pdf/6082E0414002.pdf., Accessed 27 September 2016.

Ikeda, K., Nagasawa, M., Mori, H., et al. (1992). Cloning and expression of the ε4 subunit of the NMDA receptor channel. FEBS Letters., 313, p. 34–38.

Jhamandas, K., Marien, M. (1987). Glutamate-evoked release of endogenous brain dopamine: Inhibition by an excitatory amino acid antagonist and an enkephalin analogue. British Journal of Pharmacology., 90, p. 641–650.

Johnson, JW., Ascher, P. (1987). Glycine potentiates the NMDA response in cultured mouse brain neurons.Nature, 325, p. 529–531.

Jonas, P., Monyer, H., (2010). Ionotropic glutamate receptors in the CNS. Springer-Verlag Berlin and Heidelberg GmbH & Co. K, Germany.

Kessler, M., Terramani, T., Lynch, G., Baudry, M. (1989). A Glycine site associated with N-Methyl-d-Aspartic acid receptors: Characterization and identification of a new class of antagonists. Journal of Neurochemistry, 52, p. 1319–1328.

Kinney, WA., Lee, NE., Garrison, DT., et al. (1992). Bioisosteric replacement of the .alpha.-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3, 4-diamino-3-cyclobutene-1, 2-dione containing NMDA antagonists. Journal of Medicinal Chemistry, 35, p. 4720–4726.

Kleckner, N., Dingledine, R. (1988). Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science. 241, p. 835–837.

Korczyn, AD., Nussbaum, M. (2002). Emerging therapies in the pharmacological treatment of Parkinson???S disease. Drugs, 62, p. 775–786.

Krebs, MO., Desce, JM., Kemel, ML., et al. (1991). Glutamatergic control of Dopamine release in the rat Striatum: Evidence for Presynaptic N-Methyl-D-Aspartate receptors on Dopaminergic nerve terminals. Journal of Neurochemistry., 56, p. 81–85.

Leeson, PD., Iversen, LL. (1994). The Glycine site on the NMDA receptor: Structure-activity relationships and therapeutic potential. Journal of Medicinal Chemistry., 37, p. 4053–4067.

Leverenz, J., Sumi, SM. (1986). Parkinson’s disease in patients with Alzheimer’s disease. Archives of Neurology , 43, p. 662–664.

Liang, X., Wang, RY. (1998). Biphasic modulatory action of the selective sigma receptor ligand SR 31742A on N-methyl-d-aspartate-induced neuronal responses in the frontal cortex. Brain Research, 807, p. 208–213.

Lipton, SA., Nakanishi, N., Das, S., et al. (1998). Increased NMDA Current and Spine Density in Mice Lacking the NMDA Receptor Subunit NR3A. Nature., 393, p. 377–381.

Lipton, SA. (2006). Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond.Nature Reviews Drug Discovery, 5, p. 160–170.

Madry. (2010). Potentiation of glycine-gated NR1/NR3A NMDA receptors relieves ca2+-dependent outward rectification. Frontiers in Molecular Neuroscience, 3, p. 1-6.

Mallamo, JP., Earley, WG., Kumar, V., et al. (1994). Identification, synthesis, and characterization of a unique class of N-Methyl-D-aspartate antagonists. The 6, 11-Ethanobenzo[b]quinolizinium Cation. Journal of Medicinal Chemistry., 37, p. 4438–4448.

Mann, V., Cooper, JM., Krige, D., Daniel, Se., Schapira, Ahv., Marsden, CD. (1992). Brain, Skeletal Muscle And Platelet Homogenate Mitochondrial Function In Parkinson’s Disease.Brain., 115, p. 333–342.

Masu, M., Nakajima, Y., Moriyoshi, K., Ishii, T., Akazawa, C., Nakanashi, S. (1993). Molecular characterization of NMDA and Metabotropic glutamate receptors. Annals of the New York Academy of Sciences., 707, p. 153–164.

Mitchell, PR., Doggett, NS. (1980). Modulation of striatal [3H]-glutamic acid release by dopaminergic drugs. Life Sciences. , 26, p. 2073–2081.

Molsa, PK., Marttila, RJ., Rinne, UK. (1984). Extrapyramidal signs in Alzheimer’s disease. Neurology., 34, p. 1114–1114.

Monyer, H., Sprengel, R., Schoepfer, R., et al. (1992). Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science., 256, p. 1217–1221.

Monyer, H., Burnashev, N., Laurie, DJ., Sakmann, B., Seeburg, PH. (1994). Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron., 12, p. 529–540.

Mount, H., Quirion, R., Chaudieu, I., Boksa, P. (1990). Stimulation of Dopamine release from cultured rat Mesencephalic cells by naturally occurring excitatory amino acids: Involvement of Both N-Methyl-D-Aspartate (NMDA) and Non-NMDA receptor subtypes. Journal of Neurochemistry., 55, p. 268–275.

Nieoullon, A., Cheramy, A., Glowinski, J. (1978). Release of dopamine evoked by electrical stimulation of the motor and visual areas of the cerebral cortex in both caudate nuclei and in the substantia nigra in the cat. Brain Research. , 145, p. 69–83.

Ryan, TJ, Grant, SGN. (2009). The origin and evolution of synapses. Nature Reviews Neuroscience., 10, p.701–712.

Renzi, M., Farrant, M., Cull-Candy, SG. (2007). Climbing-fibre activation of NMDA receptors in Purkinje cells of adult mice. The Journal of Physiology., 585, p. 91–101.

Session 20 Synaptic plasticity and Neurogenesis. http://science.mcmaster.ca/pnb/images/stories/ courses/psych2c3ls/session_20.pdf. Accessed 27 September 2016.

Stephenson, FA. (2006). Structure and trafficking of NMDA and GABA A receptors. Biochemical Society Transactions , 34, p. 877–881.

Traynelis, SF., Wollmuth, LP., McBain, CJ., et al. (2010). Glutamate receptor ion channels: Structure, regulation, and function. Pharmacological Reviews. , 62, p. 405–496.

Vyklicky, V., Korinet, M., Smejkalova, T., et al. (2014). Structure, Function, and Pharmacology of NMDA Receptor Channels. Physiological Research. , 63, p. S191–S203.

Verdoorn, T., Kleckner, N., Dingledine, R. (1987). Rat brain N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Science. , 238, p. 1114–1116.

Weihmuller, FB., Ulas, J., Nguyen, L., Cotman, CW., Marshall, JF. (1992). Elevated NMDA receptors in Parkinsonian striatum. NeuroReport, 3, p. 977–980.

Westerink, BHC., Santiago, M., De Vries, JB. (1992). The release of dopamine from nerve terminals and dendrites of nigrostriatal neurons induced by excitatory amino acids in the conscious rat. Naunyn-Schmiedeberg's Archives of Pharmacology., 345, p. 523–529.

Wong, T., Howland, JG., Wang, YT. (2009). NMDA Receptors and Disease+C464. Encyclo Neuroscience, 2009, p.1177–1182.

Zhou, L-M., Szendrei, GI., Fossom, LH., Maccecchini, M-L., Skolnick, P., Otvos, L. (2002). Synthetic analogues of Conantokin-G: NMDA antagonists acting through a novel Polyamine-Coupled site. Journal of Neurochemistry.. , 66, p. 620–628.

Zhuo, M. (2005). Targeting central plasticity: A new direction of finding painkillers. Current Pharmaceutical Design. , 11, p. 2797–2807.

Zukin, RS., Bennett, MVL. (1995). Alternatively spliced isoforms of the NMDARI receptor subunit. Trends in Neurosciences. , 18, p. 306–313.


Refbacks

  • There are currently no refbacks.




Copyright © 2015 BIOPHARM JOURNAL  - ISSN 2454-1397 & Powered by Sona Nfinity